BioNTech, Fosun Pharma Vaccinate Patients in New Phase 1 Chinese Study

Germany-based BioNTech and Fosun Pharma have begun a phase 1 trial of their COVID-19 vaccine candidate in China.

The trial will include a total of 144 patients, who will either receive two 10-microgram or 30-microgram doses of the messenger RNA-based vaccine candidate BNT162b1 or a placebo.

BioNTech is supplying the vaccine for the China trial from its manufacturing facilities in Europe.